Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay

Pharmacogenetics

Volumn 10, Issue 4, 2000, Pages 293-300

  Lo Guidice, Jean Marc ^a   Allorge, Delphine ^a   Chevalier, Dany ^a   Debuysère, Hervé ^a   Fazio, Fany ^a   Lafitte, Jean Jacques ^a   Broly, Franck ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Genetic polymorphism; NAT1; SSCP

Indexed keywords

ACYLTRANSFERASE; DNA;

ALLELE; ARTICLE; DNA FLANKING REGION; DNA SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0034117642     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200006000-00003     Document Type: Article

References (31)

1. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine N-acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995; 55:5230-5237.
2. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995a; 55:5226-5229.
3. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk for colorectal cancer. Cancer Res 1995b; 55:3557-3542.
4. Blum M, Grant DM, Mc-Bride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 1990; 9:193-203.
5. Bouchardy C, Mitrunen K, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998; 8:291-298.
6. Broly F, Marez D., Sabbagh N, Legrand M, Millecamps S, Lo Guidice J-M, et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene. Pharmacogenetics 1995; 5:373-384.
7. Butcher NJ, Ilett KF, Minchin RF. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenctics 1998; 8:67-72.
8. Cribb AE, Grant DM, Miller MA, Spielberg SP. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leucocytes. J Pharmacol Exp Therap 1991; 259:1241-1246.
9. Deitz AC, Doll MA, Hein DW. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem 1997; 253:219-224.
10. Glavac D, Dean M. Optimisation of the single strand conformation polymorphism technique for detection of point mutations. Hum Mutat 1993; 5:404-414.
11. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993; 3:45-50.
12. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver enzymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39:184-191.
13. Grant DM, Vohra P, Avis Y, Ima A. Detection of a new polymorphism of human arylamine N-acetyltransferase NAT1 using p-aminosalicylic acid as an in vivo probe. J Basic Clin Physiol Pharmacol 1992; 3:244.
14. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, et al. Human acetyltransferase polymorphisms. Mutat Res 1997; 376:61-70.
15. Hayashi K, Wandell DW. How sensitive is PCR-SSCP? Hum Mutat 1993; 5:338-346.
16. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14:1633-1638.
17. Hughes NC, Janezic SA, MacQueen KL, Jewett MAS, Castranio T, Bell DA, Grant DM. Identification and characterization of variant alleles of human N-acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998; 8:55-66.
18. Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 1992; 98:69-74.
19. Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louie AD, Kau IH, et al. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 1998; 8:269-281.
20. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte J-J, et al. Polymorphism of the cytochrome P450 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
21. Meyer UA. Polymorphism of human N-acetyltransferases. Environ Health Perfect 1994; 102:213-216.
22. Orita M, Suzuki Y, Sejiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphism using the polymerase chain reaction. Genomics 1989; 5:874-879.
23. Payton MA, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1). The identification of two novel allelic variants. Biochem Pharmacol 1998; 55:361-366.
24. Probst MR, Blum M, Fasshauer I, D'Orazio D, Meyer UA, Wield D. The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazo [4, 5-f] quinoline (IQ). Carcinogenesis 1992; 13:1713-1717.
25. Probst-Hensch NM, Haile RW, Li DS, Sakamoto GT, Louie AD, Lin BK, et al. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis 1996; 17:2125-2129.
26. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM. The sensitivity of single-strand polymorphism analysis for the detection of single base substitution. Genomics 1993; 16:325-332.
27. Taylor JA, Umbach D, Stephens E, Paulson D, Robertson C, Mohler JL, Bell DA. Role of the N-acetylation polymorphism at NAT1 and NAT2 in smoking-associated bladder cancer. Proc Am Assoc Cancer Res 1995; 36:282.
28. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Ach Biochem Biophys 1993; 301:71-76.
29. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Price Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferase. Pharmacogenetics 1995: 5:1-17.
30. Ward A, Hickman D, Gordon J, Sim E. Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol 1992: 44:1099-1104.
31. Weber WW, Vatsis KP. Interindividual variability in p-aminobenzoic acid N-acelylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 1993; 3:209-212.